Previous 10 | Next 10 |
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of its...
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Santiago Arroyo, M.D., Ph.D., to its Board of Directors. Dr. Arroyo brings more than 30 year...
Michael Burry predicted the mortgage collapse and made huge profits as profiled in the movie "The Big Short." Last year he was very early to GameStop, earning significant profits. He added a number of bearish bets on interest rates (and Tesla!). Dipped his toes into shipping. ...
Marinus Pharmaceuticals, Inc. (MRNS) Q1 2021 Earnings Conference Call May 17, 2021 08:30 ET Company Participants Sasha Damouni - Vice President, Investor Relations and Corporate Communications Scott Braunstein - Chief Executive Officer Joe Hulihan - Chief Medical Officer Christy Shafer - Chie...
The following slide deck was published by Marinus Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Marinus Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
Marinus Pharmaceuticals (MRNS): Q1 GAAP EPS of -$0.74 misses by $0.29.Revenue of $1.81M misses by $0.75M.Cash, cash equivalents, and investments of $123.5M.The company believes its cash and cash equivalents as of March 31, 2021 combined with the net upfront proceeds of the Oaktree credit faci...
Strategic credit financing agreement with funds managed by Oaktree Capital Management, L.P. (“Oaktree”) will provide up to $125 million to support continued development and commercial readiness of both the oral and IV ganaxolone programs On track to submit NDA for us...
New Date and Time: Monday, May 17 at 8:30 AM Eastern Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it has rescheduled its Fiscal First Quart...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it plans to release financial results for the first quarter ended March 31, 2021 after the market close on ...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following virtual investor conferences: B. Ri...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...